Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Inclusion Criteria

• •1. Participants must meet protocol defined disease criteria requiring treatment for their respective disease prior to initiation of ibrutinib or acalabrutinib
• •2. Ibrutinib and acalabrutinib intolerance is defined as an unacceptable toxicity where, in the opinion of the investigator, treatment should be discontinued in spite of optimal supportive care as a result of one of the following:
• •1. For ibrutinib and acalabrutinib intolerance events:
• •* 1 or more ≥ Grade 2 nonhematologic toxicities for \>7 days (with or without treatment)
• •* 1 or more ≥ Grade 3 nonhematologic toxicity of any duration
• •* 1 or more Grade 3 neutropenia with infection or fever of any duration; or
• •* Grade 4 heme toxicity which persists to the point that the investigator chose to stop therapy due to toxicity NOT progression.
• •2. For acalabrutinib intolerance events only;
• •* 1 or more ≥ Grade 1 nonhematologic toxicities of any duration with \> 3 recurrent episodes; or
• •* 1 or more ≥ Grade 1 nonhematologic toxicities for \> 7 days (with or without treatment); or
• •* Inability to use acid-reducing agents or anticoagulants (eg, proton pump inhibitors, warfarin) due to concurrent acalabrutinib use
• •3. Ibrutinib and/or acalabrutinib-related ≥ Grade 2 toxicities must have resolved to ≤ Grade 1 or baseline prior to initiating treatment with zanubrutinib. Grade 1 acalabrutinib-related toxicities must have resolved to Grade 0 or baseline prior to initiating treatment with zanubrutinib.
• •4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
• •5. Absolute neutrophil count (ANC) ≥ 1000/mm\^3 with or without growth factor support and platelet count ≥ 50,000/mm\^3 (may be post-transfusion), on or prior to C1D1 of zanubrutinib